Infectious Disease
RSSArticles
-
FDA Authorizes Updated Boosters to Protect Against Omicron
Agency prepares for potential cold weather COVID-19 case spike with latest vaccine solution.
-
Is It Possible to Sway Hesitant Patients to Take the COVID-19 Vaccine?
A survey conducted in a small New York county reveals some challenges moving forward.
-
COVID-19 Infection More Likely to Inflame Heart Than Vaccine
Researchers noted patients were much more likely to be afflicted with myocarditis after a SARS-CoV-2 infection than after receiving a vaccine.
-
U.S. N95 Respirator Supply Finally Deemed Adequate
Federal regulators remove devices from shortage list.
-
COVID-19: Duration of Shedding of Transmissible Virus
Patients with COVID-19 were found, by culture, to shed replication-competent virus after an initial PCR test for median durations of four to five days.
-
COVID-19 Rebound
Symptomatic and virologic recrudescence after treatment of patients with COVID-19 with Paxlovid occurs in a tiny percentage of patients and generally is mild and self-limited.
-
Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
Novavax is authorized to be administered to patients age 18 years and older for active immunization to prevent COVID-19 caused by SARS-CoV-2.
-
Parechovirus Meningoencephalitis in Infants
Parechovirus A3 is a leading cause of meningoencephalitis in infants.
-
Ibrexafungerp for Vulvovaginal Candidiasis
The authors of a randomized clinical trial compared one day of oral ibrexafungerp with placebo for women with vulvovaginal candidiasis (VVC). They found ibrexafungerp to be safe and effective, with mild diarrhea the most common adverse event. Ibrexafungerp differs mechanistically from azoles and appears to be a promising new treatment for VVC.
-
Marburg Virus Outbreak in Ghana — Should We Worry?
An outbreak of Marburg virus disease, an illness resembling Ebola, is occurring in Ghana, only the second such event in West Africa. Will it spread beyond Africa?